(Reuters) -Sage Therapeutics claimed on Monday that its board has really all denied the requisition deal it obtained from Biogen.
The agency claimed Biogen’s present to accumulate all distinctive shares of Sage that it doesn’t at present possess for $7.22 every, “significantly undervalues Sage and believes it is not in the best interest of shareholders.”
Biogen has a ten.2% danger in Sage Therapeutics.
Sage claimed it has really launched a process to find tactical decisions, nonetheless has not set up a schedule for the analysis process.
(Reporting by Sneha S Okay; Editing by Tasim Zahid)
